RESUMEN
The glypicans compose a family of glycosylphosphatidylinositol-anchored heparan sulfate proteoglycans that may play a role in the control of cell division and growth regulation. So far, six members (GPC1-6) of this family are known in vertebrates. We report the construction of a high-resolution 4 Mb sequence-ready BAC/PAC contig of the GPC5/GPC6 gene cluster on chromosome region 13q32. The contig indicates that, like the GPC3/GPC4 genes on Xq26, GPC5 and GPC6 are arranged in tandem array. Both GPC5 and GPC6 are very large genes, with sizes well over 1 Mb. With a size of approximately 2 Mb, GPC5 would be the second largest human gene identified to date. Comparison of the long range gene organisation on 13q and Xq, suggests that these chromosomes share several regions of homology. Mutations and deletions affecting GPC3 are associated with the Simpson-Golabi-Behmel overgrowth syndrome. Mutational analysis of GPC5 and GPC6 in 19 patients with somatic overgrowth failed to reveal pathologic mutations in either of these genes, but identified several coding region polymorphisms.
Asunto(s)
Cromosomas Humanos Par 13/genética , Mapeo Contig/métodos , Proteoglicanos de Heparán Sulfato/genética , Familia de Multigenes/genética , Secuencia de Bases , Síndrome de Beckwith-Wiedemann/genética , Exones/genética , Proteínas de la Matriz Extracelular , Glipicanos , Humanos , Datos de Secuencia Molecular , Polimorfismo Genético/genética , Homología de SecuenciaRESUMEN
Novel photoactivatable antagonists of human/rat corticotropin-releasing factor (h/rCRF) have been synthesized and characterized. The N-terminal amino acid D-phenylalanine in astressin ¿cyclo(30-33) [D-Phe12, Nle21,38, Glu30, Lys33]h/rCRF-(12-41)¿, a potent CRF peptide antagonist, was replaced by a phenyldiazirine, the 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB) residue. Additionally, His32 of astressin was substituted by either alanine or tyrosine for specific radioactive labeling with 125I at either His13 or Tyr32, respectively. The photoactivatable CRF antagonists were tested for their ability to displace 125I-labeled Tyr0 ovine CRF ([125I-labeled Tyr0]oCRF) in binding experiments and to inhibit oCRF-stimulated adenylate cyclase activity in human embryonic kidney (HEK) 293 cells, permanently transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1) or human Y-79 retinoblastoma cells known to carry endogenous functional human CRFR1 (hCRFR1). ATB-cyclo(30-33)[Nle21,38, Glu30, Ala32, Lys33]h/rCRF-(13-41) (compound 1) was found to bind with higher affinity to rat or human CRFR1 when compared with ATB-cyclo(30-33)[Nle21,38, Glu30, Tyr32, Lys33]h/rCRF-(13-41) (compound 2) and exhibited higher inhibition of oCRF-stimulated cAMP accumulation in HEK 293 cells stably transfected with cDNA coding for rCRFR1 (HEK-rCRFR1 cells) or Y-79 cells. A highly glycosylated, 66-kDa protein was identified with SDS/PAGE, when the radioactively iodinated compounds 1 or 2 were covalently linked to rCRFR1. The specificity of the photoactivatable 125I-labeled CRF antagonists was demonstrated with SDS/PAGE by the finding that these analogs could be displaced from the receptor by their corresponding nonlabeled form, but not other unrelated peptides such as vasoactive intestinal peptide. The observed molecular size of the receptor was in agreement with the size of CRFR1 found in rat pituitary (66 kDa), but was significantly larger than the size of CRFR1 found in rat cerebellum and olfactory bulb (53 kDa).
Asunto(s)
Hormona Liberadora de Corticotropina/antagonistas & inhibidores , Etiquetas de Fotoafinidad/química , Etiquetas de Fotoafinidad/metabolismo , Receptores de Hormona Liberadora de Corticotropina/química , Receptores de Hormona Liberadora de Corticotropina/metabolismo , Adenilil Ciclasas/metabolismo , Secuencia de Aminoácidos , Animales , Azidas/síntesis química , Línea Celular , Membrana Celular/metabolismo , Cerebelo/metabolismo , Hormona Liberadora de Corticotropina/química , AMP Cíclico/metabolismo , ADN Complementario/metabolismo , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Poliacrilamida , Fluorobencenos/síntesis química , Glicosilación , Histidina/química , Humanos , Cinética , Datos de Secuencia Molecular , Fármacos Neuroprotectores/química , Bulbo Olfatorio/metabolismo , Fragmentos de Péptidos/química , Hipófisis/metabolismo , Unión Proteica , Ratas , Transfección , Células Tumorales Cultivadas , Tirosina/químicaRESUMEN
The structure-activity relationship (SAR) between the recently identified neuropeptide urocortin (Ucn) and corticotropin-releasing factor (CRF) receptor, type 1 (CRFR1), has been investigated. To this end, rat Ucn (rUcn), ovine CRF (oCRF) and chimeric peptides of rUcn and oCRF were synthesized and tested for their binding affinity and potency to stimulate cAMP production in human embryonic kidney (HEK) 293 cells stably transfected with cDNA encoding rat CRFR1 (rCRFR1). In binding studies with [125I-TyrO]oCRF or [3H-Leu9]rUcn as radioligand, it was observed that rUcn but not oCRF bound in a similar fashion as the CRF antagonist astressin with high affinity to rCRFR1 coupled to G protein or uncoupled from G protein by guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). Consequently, rUcn was found to exert a significantly lower potency than oCRF to stimulate cAMP accumulation in transfected cells. CD spectroscopic investigations and reverse-phase HPLC (RPHPLC) retention behavior of the peptides suggested a more pronounced amphipatic alpha-helical character of rUcn when compared to oCRF and the chimeric peptides.
Asunto(s)
Hormona Liberadora de Corticotropina/metabolismo , Proteínas de Unión al GTP/metabolismo , Fragmentos de Péptidos/metabolismo , Receptores de Hormona Liberadora de Corticotropina/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular , Cromatografía Líquida de Alta Presión , Dicroismo Circular , Hormona Liberadora de Corticotropina/química , AMP Cíclico/biosíntesis , Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Humanos , Datos de Secuencia Molecular , Unión Proteica , Ratas , Proteínas Recombinantes/metabolismo , Homología de Secuencia de Aminoácido , Ovinos , UrocortinasRESUMEN
Different truncated and conformationally constrained analogs of corticotropin-releasing factor (CRF) were synthesized on the basis of the amino acid sequences of human/rat CRF (h/rCRF), ovine CRF (oCRF), rat urocortin (rUcn), or sauvagine (Svg) and tested for their ability to displace [125I-Tyr0]oCRF or [125I-Tyr0]Svg from membrane homogenates of human embryonic kidney (HEK) 293 cells stably transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1), or mouse CRF receptor, type 2beta (mCRFR2beta). Furthermore, the potency of CRF antagonists to inhibit oCRF- or Svg-stimulated cAMP production of transfected HEK 293 cells expressing either rCRFR1 (HEK-rCRFR1 cells) or mCRFR2beta (HEK-mCRFR2beta cells) was determined. In comparison with astressin, which exhibited a similar affinity to rCRFR1 (Kd = 5.7 +/- 1.6 nM) and mCRFR2beta (Kd = 4.0 +/- 2.3 nM), [DPhe11,His12]Svg(11-40), [DLeu11]Svg(11-40), [DPhe11]Svg(11-40), and Svg(11-40) bound, respectively, with a 110-, 80-, 68-, and 54-fold higher affinity to mCRFR2beta than to rCRFR1. The truncated analogs of rUcn displayed modest preference (2- to 7-fold) for binding to mCRFR2beta. In agreement with the results of these binding experiments, [DPhe11, His12]Svg(11-40), named antisauvagine-30, was the most potent and selective ligand to suppress agonist-induced adenylate cyclase activity in HEK cells expressing mCRFR2beta.
Asunto(s)
Hormona Liberadora de Corticotropina/análogos & derivados , Hormona Liberadora de Corticotropina/farmacología , Fragmentos de Péptidos/farmacología , Conformación Proteica , Receptores de Hormona Liberadora de Corticotropina/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Unión Competitiva , Línea Celular , Hormona Liberadora de Corticotropina/síntesis química , Hormona Liberadora de Corticotropina/química , Reactivos de Enlaces Cruzados , AMP Cíclico/metabolismo , Humanos , Riñón , Cinética , Ratones , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Estructura Secundaria de Proteína , Ratas , Receptores de Hormona Liberadora de Corticotropina/genética , Receptores de Hormona Liberadora de Corticotropina/fisiología , Proteínas Recombinantes/antagonistas & inhibidores , Alineación de Secuencia , Homología de Secuencia de Aminoácido , TransfecciónRESUMEN
A major reorganization of afferent and efferent nerve terminals, concomitant to significant neuronal cell loss and pruning of superfluous fibers, takes place during the development of the organ of Corti, prior to the onset of hearing. We examined the spatio/temporal distribution of subtype-specific AMPA- and N-methyl-d-aspartate (NMDA)-selective glutamate receptor proteins in postnatal inner ears from rats during this critical period. From the first postnatal day onwards, GluR2/3 receptor subtypes appeared in nerve endings of afferent fibers associated with inner and outer hair cells. During the following 2 weeks, GluR2/3 receptors were downregulated in exchange for GluR4 receptors. In parallel efferents projecting from the medial olivocochlear complex to the outer hair cells underwent synaptogenesis and efferents projecting from the lateral olivocochlear complex to the inner hair cells appeared to change contacts to the dendrites of afferents. Concomitant to these events, NMDA receptor subtypes NR1 and NR2A transiently appeared in hair cells as well as afferent and efferent fibers. Recently, we described a temporary expression of the neurotrophin receptor trkB in hair cells, coincident to the growth (GAP-43) and synaptogenesis (synaptophysin) of efferents. Here, we show that trkB was expressed together with NR1 receptors in hair cells in high spatio/temporal correlation with the rearrangement of afferents and efferents. Cochlea NMDA receptors may, therefore, be a part of the mechanism by which, in addition to neurotrophic activity, the mature phenotype of cochlea neurons is acquired through activity-dependent processes.
Asunto(s)
Cóclea/inervación , Fibras Nerviosas/metabolismo , Receptores AMPA/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Animales , Cóclea/crecimiento & desarrollo , Cóclea/metabolismo , Técnica del Anticuerpo Fluorescente Indirecta , Ratas , Ratas Sprague-DawleyRESUMEN
N-Methyl-D-aspartate (NMDA) receptor subunits were characterized with seven polyclonal antibodies. The antibodies were directed against NR1-A, NR2A-N1, and NR2C-N1, representing N-terminal sequences of the NR1, NR2A, and NR2C subunits, and against NR1-E, NR2A-C1, and NR2C-C1, derived from C-terminal sequences of these subunits. The anti-NR1-D antibody was raised against the putative internal loop of NR1. A size of 118 kDa was found in sodium dodecyl sulfate-polyacrylamide gel electrophoresis for NR1 (from rat brain) detected by anti-NR1-D and -NR1-E, but not anti-NR1-A. With the anti-NR1-A antibody, a 125-kDa protein was discovered that may represent a glutamate receptor not yet characterized. NR2A and NR2C were identified as proteins with sizes of 175 and 140 kDa, respectively. Enzymatic N-deglycosylation generated a 97-kDa protein from NR1, a 105-kDa protein from the 125-kDa protein, a 162-kDa protein from NR2A, and a 127-kDa protein from NR2C. In contrast to the deglycosylation product of the NR2A, the 97- and 127-kDa proteins derived from NR1 and NR2C, respectively, were found significantly smaller than the molecular masses of 103 and 141 kDa, respectively, predicted on the basis of DNA data. These products may represent truncated proteins. The tissue content of the NR1 and NR2A was high in bovine hippocampus and cortex but lower in the cerebellum. In contrast, NR2C was solely found in the cerebellum. The 125-kDa protein was highest in the cerebellum and cortex.